Regulatory T cells and CD20+ B cells in pediatric very severe aplastic anemia: possible clinical markers for evaluating the therapeutic efficacy and prognosis

Hematology. 2018 Dec;23(10):823-827. doi: 10.1080/10245332.2018.1498566. Epub 2018 Jul 11.

Abstract

Objectives: To investigate the immune status of children with very severe aplastic anemia (VSAA), and evaluate the frequencies of CD20+ B cells and Regulatory T cells (Tregs) as potential markers for evaluating the therapeutic efficacy and prognosis.

Methods: We systematically analyzed CD20+ B cells and Tregs using Flow Cytometry in 36 children with VSAA (14 newly diagnosed cases and 22 cases in remission after therapy with HDIVIG + r-ATG + CSA).

Results: In newly diagnosed VSAA patients, the percentage of CD20+ B cells was higher than that in healthy children (P < .01), whereas the percentage of Tregs was lower than that in healthy children (P < .001). After treatment with HDIVIG + r-ATG + CSA, the percentage of CD20+ B cells in peripheral blood was decreased obviously, and the percentage of Tregs was significantly increased.

Conclusion: There is a moderate negative correlation between the percentage of Tregs and CD20+ B cells in our study. Our results shed light on the roles of Tregs and CD20+ B cells as therapeutic efficacy and prognostic markers of pediatric VSAA. Moreover, the mechanism underlying the decrease of blood Tregs and increase of CD20+ B cells in pediatric VSAA patients have been discussed, indicating that Tregs may suppress B cell responses.

Keywords: CD20+ B cells; Tregs; Very severe aplastic anemia; pediatrics.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Anemia, Aplastic* / blood
  • Anemia, Aplastic* / drug therapy
  • Anemia, Aplastic* / immunology
  • Antigens, CD20* / blood
  • Antigens, CD20* / immunology
  • Antilymphocyte Serum / administration & dosage*
  • B-Lymphocytes* / immunology
  • B-Lymphocytes* / metabolism
  • Biomarkers / blood
  • Child
  • Child, Preschool
  • Cyclosporine / administration & dosage*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Infant
  • Male
  • Severity of Illness Index
  • T-Lymphocytes, Regulatory* / immunology
  • T-Lymphocytes, Regulatory* / metabolism

Substances

  • Antigens, CD20
  • Antilymphocyte Serum
  • Biomarkers
  • Immunoglobulins, Intravenous
  • Cyclosporine